Project Grant R01GM157408
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Illinois $614,467 on April 1, 2026, through the Biomedical Research and Research Training program (CFDA 93.859) to develop switchable artificial metalloproteins (SWARMs) that model conformational control in metalloenzyme reactivity. The research, led by principal investigator Lisa Olshansky, combines synthetically prepared metal...
- The National Science Foundation Division of Chemistry awarded the University of Illinois $600,000 on August 15, 2026, under the Mathematical and Physical Sciences program (CFDA 47.049) to investigate low-valent nickel-isocyanide compounds and their role in organometallic catalysis. Dr. Liviu M. Mirica of the Department of Chemistry at the University of Illinois Urbana-Champaign will synthesize and characterize novel mononuclear and binuclear nickel(I) complexes with tert-butyl isocyanide...
- The National Institute of General Medical Sciences, a component of the National Institutes of Health, awarded The University of Chicago $590,711 in project grant funding on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The funding supports development of new synthetic methods to accelerate preparation of diverse analogues for medicinal chemistry studies. Over the five-year performance period ending June 30, 2031, the research addresses carbon-carbon...
- The National Institutes of Health Office of the Director awarded the University of Wisconsin–Madison $714,809 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to discover and engineer nickel biocatalysts for precise tailoring of therapeutics. The research develops enzymes that control nickel-catalyzed reactions, merging nickel's reaction versatility with enzymatic selectivity. The project pursues three synergistic innovations: a bioinformatic pipeline to...
- The National Institute of General Medical Sciences awarded the University of Chicago $421,293 on July 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support synthetic modeling research in bioinorganic oxidation chemistry led by the Anderson Laboratory. The award funds a synthetic modeling program investigating principles governing the oxidative activity of metalloenzymes. The research synthesizes and leverages molecular model complexes to study emerging...
- The National Institute of General Medical Sciences awarded $1,184,200 to the University of Montana on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop high-valent dinuclear cobalt-oxo complexes for studying enzymatic bond activation and formation processes. The project runs through March 31, 2030, with work performed in Missoula, Montana. The research uses biomimetic and bio-inspired first-row transition metal complexes to understand how natural...
- The National Institute of General Medical Sciences awarded the University of California, San Diego $507,265 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct design and mechanistic investigations of metalloenzymes and metalloproteins. The award funds research combining top-down study of natural metalloenzymes with bottom-up design of artificial ones. The primary focus is nitrogenase, the only known biological system capable of...
- The National Institute of General Medical Sciences awarded the University of Rochester $448,196 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop synthetic tools for constructing carbon-nitrogen bonds using N-aryl and N-alkenyl nitrogen intermediates. The research targets the synthesis of nitrogen heterocycles, which are critical structural components in pharmaceuticals and natural products. The project will develop catalytic methods to...
- The National Institute of General Medical Sciences awarded the University of Illinois $303,685 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to discover and characterize RIPP biosynthetic enzymes. The work focuses on assigning catalytic function to domains of unknown function (DUFs) encoded in microbial genomes, particularly those involved in ribosomally synthesized and posttranslationally modified peptides (RIPPs) biosynthesis. The research...
- The National Institute of General Medical Sciences awarded the University of California, Los Angeles $420,981 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop engineered enzymatic catalysts for asymmetric hydrogen atom transfer reactions in synthetic chemistry. The research integrates organic chemistry, protein engineering, bioinorganic chemistry, and computational modeling to design and evolve biocatalysts that enable...
The National Institute of General Medical Sciences awarded $338,892 to the University of Illinois on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) for organometallic chemistry research on nickel enzymes. The project focuses on developing catalytic and functional mimics of acetyl-coenzyme A synthase (ACS) and [NiFe] hydrogenase through the design of flexible multidentate ligands with mixed hard/soft donor atoms. The research aims to detect and characterize low- and high-valent organometallic nickel species that serve as key reactive intermediates during catalysis. Work under Aim 1 will probe the paramagnetic and diamagnetic mechanisms of ACS mimics, including thermodynamics and kinetics of carbon monoxide reactivity during reversible migratory insertion and subsequent reactions with thiolate substrates. Aim 2 will examine reactivity of [NiFe] hydrogenase mimics based on a recently developed nickel biomimetic catalyst for hydrogen evolution. The research targets enzymes required for the survival of human pathogens including Clostridium difficile and Helicobacter pylori. Performance occurs in Champaign, Illinois, with a period of performance extending from September 1, 2026, through April 30, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $338.9k | 8/14/26 |